Ibuprofen inhibits migration and proliferation of human coronary artery smooth muscle cells by inducing a differentiated phenotype: role of peroxisome proliferator-activated receptor y by Dannoura, Abeer et al.
Ibuprofen inhibits migration and 
proliferation of human coronary artery 
smooth muscle cells by inducing a 
differentiated phenotype: role of 
peroxisome proliferator­activated receptor 
y 
Article 
Accepted Version 
Dannoura, A., Giraldo, A., Pereira, I., Gibbins, J., Dash, P., 
Bicknell, K. and Brooks, G. (2014) Ibuprofen inhibits migration 
and proliferation of human coronary artery smooth muscle 
cells by inducing a differentiated phenotype: role of 
peroxisome proliferator­activated receptor y. Journal of 
Pharmacy and Pharmacology, 66 (6). pp. 779­792. ISSN 
0022­3573 doi: https://doi.org/10.1111/jphp.12203 Available at 
http://centaur.reading.ac.uk/40518/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work. 
To link to this article DOI: http://dx.doi.org/10.1111/jphp.12203 
Publisher: Royal Pharmaceutical Society 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
 1 
TITLE: Ibuprofen inhibits migration and proliferation of human coronary artery 
smooth muscle cells by inducing a differentiated phenotype: Role of peroxisome 
proliferator-activated receptor γ 
 
 
AUTHORS: Abeer Dannoura*, Alejandro Giraldo*, Ines Pereira, Jonathan M. Gibbins, Philip 
R. Dash, Katrina A. Bicknell and Gavin Brooks. 
School of Pharmacy, University of Reading (A.D., I.P., K.A.B.,), School of Biological 
Sciences (A.G., J.M.G., P.R.D., G.B) University of Reading, Institute for Cardiovascular and 
Metabolic Research, University of Reading, Whiteknights Campus (A.D., A.G., J.M.G., 
P.R.D., K.A.B., G.B), RG6 6UR, United Kingdom. 
E-mails: Abeer Dannoura: adannoura@yahoo.co.uk; Alejandro Giraldo: 
a.giraldoramirez@reading.ac.uk; Ines Pereira:inesgdapereira@gmail.com; Jonathan M. 
Gibbins: j.m.gibbins@reading.ac.uk; Phil R. Dash: p.r.dash@reading.ac.uk; Katrina A. 
Bicknell: k.bicknell@reading.ac.uk; Gavin Brooks: g.brooks@reading.ac.uk. 
 
 
Keywords: CAD, coronary artery disease; DES, drug eluting stent; HCASMCs, human 
coronary artery smooth muscle cells; HCAECs, human coronary artery endothelial cells; 
NSAIDs, non-steroidal antinflammatory drugs; PCI, percutaneous coronary intervention; 
PPAR, peroxisome proliferator activated receptor. 
 
*these authors contributed equally to this work 
 
 2 
  
 3 
Running title: Ibuprofen modulates human VSMC phenotype 
 
Correspondence: Professor Gavin Brooks, Address: University of Reading, Whiteknights, 
PO Box 217, Reading, Berkshire, RG6 6AH, United Kingdom. Telephone: +44-(0)118-378-
6140, Fax: +44-(0)118-987-4062, E-mail: g.brooks@reading.ac.uk.  
  
 4 
Abstract 
Objectives: The search for agents that are capable of preventing restenosis and reduce the 
risk of late thrombosis is of utmost importance. In this study we aim to evaluate the in vitro 
effects of ibuprofen on proliferation and migration of human coronary artery smooth muscle 
cells (HCASMCs) and on human coronary artery endothelial cells (HCAECs) migration.  
Methods: Cell proliferation was evaluated by direct cell counting using trypan blue 
exclusion. Cell migration was assessed by wound healing “scratch” assay and by time lapse 
videomicroscopy. Protein expression was assessed by immunoblotting, and morphological 
changes were studied by immunocytochemistry. The involvement of the PPARγ pathway 
was studied with the selective agonist troglitazone, and the use of selective antagonists of 
PPARγ such as PGF2α and GW9662. 
Results: We demonstrate that ibuprofen inhibits proliferation and migration of HCASMCs 
and induces a switch in HCASMCs towards a differentiated and contractile phenotype, and 
that these effects are mediated through the PPARγ pathway. Importantly we also show that 
the effects of ibuprofen are cell type specific as it does not affect migration and proliferation 
of endothelial cells.  
Conclusions: Taken together, our results suggest that ibuprofen could be an effective drug 
for the development of novel drug eluting stents, which could lead reduced rates of 
restenosis and potentially other complications of DES stent implantation. 
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Introduction 
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality 
worldwide, accounting for the death of one in three people each year.[1, 2] Of the 17.3 million 
deaths per year due to CVD, coronary artery disease (CAD) was responsible for over 40% of 
cases.[2] Current treatment modalities for CAD include percutaneous coronary intervention 
(PCI) with balloon angioplasty and stent implantation. However, despite advances in stent 
technology (e.g. drug eluting stents (DES)) that reduced substantially the rates of restenosis 
to less than 10%,[3, 4] the rates of late in-stent thrombosis, a devastating complication in 
terms of morbidity and mortality, are higher with DES compared to bare metal stents.[5] 
Recent reports suggest that the risk of late-stent thrombosis appears to be steadily present 
over time,[6, 7] and, indeed, there have been reports of these events occurring 4.5 to 5 years 
after DES implantation.[8, 9] Thus, late in-stent thrombosis remains a major problem in clinical 
practice.[10, 11] DES contain antiproliferative agents (e.g. rapamycin or paclitaxel), which 
target vascular smooth muscle cells (VSMCs) and inhibit their migration and proliferation to 
the site of injury following stent deployment, thus ultimately preventing neointimal formation 
and restenosis. However, DES also interfere with re-endothelialization of the stent struts, 
which currently is thought to play a central role in the pathogenesis of very late (>12 months) 
in-stent thrombosis observed with DES.[12, 13] With this in mind, the search for compounds 
capable of selectively inhibiting migration and proliferation of VSMCs, but sparing endothelial 
cell (EC) migration and proliferation, for use in DES is of utmost importance.  
During restenosis following stent deployment, VSMCs undergo significant changes in 
morphology and function exhibiting a “synthetic” or “dedifferentiated” phenotype, whereby 
these cells synthesize components of the extracellular matrix and exhibit characteristics 
similar to immature cells found in blood vessels during development.[14, 15] In the intact vessel 
wall, however, VSMCs exhibit a “differentiated” or contractile phenotype characterized by a 
spindle shape and increased expression of contractile proteins, which correlates with 
increased contractile ability.[15] 
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Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear hormone-
receptor superfamily.[16]  PPARγ expression has been shown to increase in the intima in 
response to injury.[17] It has been proposed that increased activity of PPARγ in blood vessels 
is important for limiting neointimal formation by enhancing the differentiation of VSMCs and 
thereby reducing their migratory ability.[18] Previous studies from our laboratory, and others, 
have demonstrated that ibuprofen, as well as certain other non-steroidal anti-inflammatory 
drugs (NSAIDs), reduces VSMC proliferation in a dose- and cell cycle-dependent manner.[19, 
20] In addition, several lines of evidence indicate that NSAIDs, including ibuprofen, have the 
ability to activate PPARγ receptors in several cell types and tissues.[21-23] Here, we confirm 
that ibuprofen inhibits proliferation and report for the first time that ibuprofen inhibits 
migration of human coronary artery smooth muscle cells (HCASMCs), and that this 
correlates with the induction of a differentiated phenotype in these cells. We also report that 
at least some of the effects of ibuprofen on HCASMCs are mediated through PPARγ. More 
importantly, we also show for the first time that the effect of ibuprofen is cell type specific as 
it does not affect migration and proliferation of endothelial cells. Taken together, our results 
suggest that ibuprofen could be a potential molecule for incorporation into DES which may 
prevent restenosis without interfering with the process of re-endothelialization, thus having 
the potential of preventing other complications stent implantation. 
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Materials and Methods 
Antibodies and reagents 
Antibodies raised against SMα-actin (ab5694), SM22α (ab14106), GAPDH (ab8245), β-actin 
(ab6276) and Lamin A (ab8980) were from Abcam (UK); antibody raised against PPARγ (sc-
7273) was from Santa Cruz Biotechnology (USA), antibody raised against ATF-2 (9226) was 
from Cell Signalling Technology (USA). Alexa Fluor 488 goat anti-mouse (A-11001), Alexa 
Fluor 594 phalloidin (A12381) and prolong® Gold anti-fade reagent with DAPI (P36935) 
were from Life Technologies (UK). Most chemicals, including ibuprofen and troglitazone 
were obtained from Sigma (UK); Mitomycin C was from Calbiochem (UK); GW9662 was 
obtained from Biomol (UK); PGF2α was from Merck Chemicals (UK). Tissue culture plates 
and dishes were from Thermo Fisher Nunc. 
 
Cell culture 
Primary human coronary artery smooth muscle cells (HCASMCs) and primary human 
coronary artery endothelial cells (HCAECs) were purchased from PromoCell (GmbH, 
Heidelberg, Germany), and cultured according to manufacturer’s instructions using 
PromoCell’s smooth muscle cell growth medium 2 (C-22062) or endothelial cell growth 
medium MV2 (C-22022), both of which contains 5% serum without antibiotics or antifungal 
agents. Passaging was according to the manufacturer’s instructions using DetachKit, also 
from PromoCell. Primary human pulmonary microvascular endothelial cells (HPMECs) were 
purchased from PromoCell (GmbH, Heidelberg, Germany). Growth media for HPMECs was 
prepared to give a final concentration of 20% (v/v) serum, and a concentration of 50μg/mL 
endothelial cell growth supplement in M199 with GlutaMAX™ medium. 
 For all experiments, cells were used between passages 3-5 and were cultured replacing 
with the same fresh growth medium described above. For proliferation assays, HCASMCs 
(1×104/ml) and HPMECs (1×104/ml) were seeded in 6-well plates. For wound healing 
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assays, HCASMCs (4×104/ml) and HCAECs (5×104/ml) were seeded overnight in 12-well 
plates to form a confluent monolayer. For time-lapse video microscopy experiments, both 
HCASMCs and HCAECs were seeded overnight at (1×104/ml) in 12-well plates. For 
immunoblotting, HCASMCs (2×105) and HCAECs (3×105) were plated in 60 mm tissue 
culture dishes. For immunostaining experiments, glass cover slides were placed in 12-well 
plates and coated with sterile 1% (v/v) gelatin in PBS, then washed in PBS and HCASMCs 
seeded at a density of 1×104/ml. 
 
Proliferation analysis 
Following an initial 24 h incubation, media was replaced without agonists (vehicle controls) 
or treated with different doses of ibuprofen. After a further 72 h, direct cell counting was 
performed by trypan blue exclusion.[20]  
 
Wound healing assay 
Migration was investigated using a wound healing “scratch” assay as described before,[24, 25] 
with minor modifications. Briefly, 24 h after plating both HCASMCs and HCAECs at the 
desired cell density, medium was replaced in the absence (control) or presence of different 
concentrations of ibuprofen or troglitazone, and in some instances with the selective PPARγ 
inhibitors, GW9662 or PGF2α.[26-28] Mitomycin C, was added one hour before scratching at a 
concentration of 0.5 µg/ml. This concentration of mitomycin C completely blocks proliferation 
of HCASMCs within 1 h of administration (data not shown). A scratch in the cell monolayer 
was then generated with a sterile 200 µl micropipette tip and images of the gap were 
captured immediately (time 0 h) and repeated at 24 h (HCASMCs) or 10 h (HCAECs) using 
a phase contrast microscope with an attached ProgRes SpeedXT core 5 digital camera 
(Jenoptik Systems GmbH) with ProgRes CapturePro 2.8.8. The extent of closure of the gap 
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(HCAECs) or migrated cell number (HCASMCs) was analysed using ImageJ (NIH, 
Bethesda). 
 
Time lapse videomicroscopy 
Time lapse video microscopy was used for in vitro real time analysis of HCASMCs and 
HCAECs migration, as described before,[29] with minor modifications. Cells were re-fed with 
fresh medium in the absence (control) or presence of agonists such as ibuprofen or 
troglitazone, plus in some instances antagonists, such as GW9662. Following treatments for 
30 min, cells were tracked for 48 h at 15 min intervals. Over 90 cells were tracked in each of 
three separate wells per condition, with images captured by a Nikon digital camera DXM 
1200 Japan (NIS-elements AR software). All microscopy stages were performed in a 
controlled environment (37°C and 5% CO2). The distance that a particular cell had migrated 
within 48 h was analysed using ImageJ software (NIH, Bethesda).   
 
Immunoblotting 
Whole cell extracts were prepared as described previously with minor modifications.[20] 
Briefly, HCASMCs or HCAECs were washed gently in ice cold PBS and scraped into 150 µl 
protein lysis buffer [50 mM Tris HCl pH 7.4, 250 mM NaCl, 5 mM EDTA pH 8.0, with freshly 
added Igepal (0.1 % v/v)], supplemented with protease inhibitors [0.3 mM AEBSF, 10 µg/ml 
Leupeptin and 2 µg/ml Aprotinin]. Samples were incubated on ice for 10 min and then 
centrifuged (10,000 ×g, 5 min, 4°C). Supernatants were transferred to fresh micro tubes and 
stored at -80°C until use.  
Nuclear extracts were prepared as described previously, with minor modifications.[30, 31] 
Briefly, HCASMCs or HCAECs were washed gently in ice cold PBS and scraped into 150 µl 
ice cold nuclear buffer A [10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.3 mM 
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Na3VO4], supplemented with protease inhibitors (0.3 mM AEBSF, 10 µg/ml Leupeptin and 2 
µg/ml Aprotinin). Samples were incubated on ice for 5 min, then centrifuged (10,000 × g, 5 
min, 4°C) and the pellets washed in 100 µl nuclear buffer A containing Igepal (0.1 % v/v). 
Samples were incubated for 5 min on ice, then centrifuged (10,000 × g, 5 min, 4°C) and the 
pellets re-suspended in 50 µl nuclear buffer C [20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 
mM MgCl2, 0.3 mM Na3VO4, 0.2 mM EDTA pH 8.0, 25% (v/v) glycerol] supplemented with 
protease inhibitors as above. Suspensions were incubated on ice for 1h with gentle 
vortexing every 15 min, then centrifuged (10,000 × g, 5 min, 4°C). Supernatants were 
transferred to fresh micro tubes and stored at -80°C until use. Protein concentrations were 
determined by the Bradford method.[32] 
Samples were boiled with 0.33 vol of SDS-polyacrylamide gel electrophoresis sample buffer 
[10% SDS (w/v), 13% glycerol v/v), 300 mM Tris HCl, pH 6.8, 130 mM DTT, 0.2% 
bromophenol blue (w/v)]. Proteins (20 µg) were separated by SDS-polyacrylamide gel 
electrophoresis using 10% (w/v) resolving gels and 6% (w/v) stacking gels, and transferred 
to nitrocellulose as described previously.[31] Nonspecific binding sites were blocked with 5% 
(w/v) non-fat milk powder in TBS-T [20 mM Tris HCl pH 7.5, 137 mM NaCl, 0.1% (v/v) 
Tween 20]. Membranes were incubated (overnight, 4 °C) with primary antibodies diluted 
(1:1000 for PPARγ to 1:20000) in TBS-T containing 5% non-fat milk powder for most 
antibodies, except PPARγ and ATF2 which were incubated in 5% (w/v) bovine serum 
albumin. Membranes were washed in TBS-T, incubated (60 min, room temperature) with 
horseradish peroxidase- (HRP-) conjugated secondary antibodies from Dako (1/5000 to 
1:25000 dilutions) in TBS-T containing 1% (w/v) non-fat milk powder, and were then washed 
in TBS-T. Bands were detected using enhanced chemiluminescence (ECL) Prime (GE 
Healthcare) and an ImageQuant LAS4000 mini digital imager (GE Healthcare). ImageQuant 
8.1 (GE Healthcare) software was used for densitometric analysis. 
 
Immunocytochemistry 
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HCASMCs were exposed to 500 µM ibuprofen for 72 h, then washed with PBS and fixed in 
4% (v/v) formaldehyde (10 min at room temperature). Following permeabilization with 0.1% 
Triton X-100 in PBS (10 min at room temperature) and incubation with 1% (w/v) BSA in PBS 
containing 0.1% Triton X-100 (20 min at room temperature) to block non-specific antibody 
binding, immunocytochemistry was performed as described previously with minor 
modifications.[31] Briefly, cover slides were incubated with mouse monoclonal primary 
antibodies against β-actin (1:1000 dilution for 60 min at 37◦C), followed by Alexa Fluor® 488 
anti-mouse secondary antibodies (1/200 dilution for 60 min, 37°C), and then incubated with 
Alexa Fluor® 594 phalloidin (1:200 dilution for 20 min at 37◦C). Washes (×3) were performed 
with PBS between incubations. After the final wash, cover slides were mounted with 
prolong® Gold anti-fade reagent with DAPI (Invitrogen) and visualized using a Zeiss AX10 
Axioskop fluorescence microscope. Images were captured using a Zeiss AxioCam MRm 
digital camera with Software AxioVision Rel 4.8.2 (Carl Zeiss MicroImaging GmbH). Colour 
images were converted to greyscale using Adobe Photoshop. 
 
Statistical Analysis  
Statistical analysis was performed with Graphpad Prism 5.0. The data are presented as 
mean ± SEM, and significance of results was determined by one-way ANOVA with Dunnet’s 
or Tukey’s post test, and, where appropriate, a paired two-tailed student t test. The results 
were considered significant when p< 0.05. 
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Results  
Proliferation and migration of HCASMCs is inhibited by ibuprofen in a dose 
dependent manner 
Proliferation and migration of VSMCs are key elements in the pathophysiology of restenosis 
post-stent implantation.[33] Previous studies from our laboratory demonstrated that A10 rat 
VSMC proliferation was inhibited by several NSAIDs in a dose-dependent manner.[20] Here, 
we first evaluated whether proliferation of human primary HCASMCs is similarly affected by 
ibuprofen. Treatment with different concentrations of ibuprofen did, indeed, cause an 
inhibitory effect on the proliferation of HCASMCs in a dose-dependent manner. Thus, whilst 
100 µM ibuprofen had no significant effect, concentrations above 250 µM progressively 
inhibited proliferation of HCASMCs, with an IC50 of 680±120 µM (Figure 1A). 
We then performed in vitro studies to evaluate the effects of ibuprofen on the migration of 
HCASMCs. Using a wound healing “scratch” assay (a well validated method for evaluating 
migration of cells in vitro),[25] we first observed that HCASMCs migrate individually rather 
than as a population of cells. Subsequent observations indicated that ibuprofen inhibits the 
number of cells that migrate to the wound in a dose-dependent manner. Thus, doses up to 
2000 µM ibuprofen were able to inhibit the migrated cell number with an IC50 of 410±60 µM 
(Figures 1B and 1C), without significant cytotoxicity for the cells (as determined by trypan 
blue exclusion assay; data not shown).  
We then used time-lapse videomicroscopy to evaluate, in real time, the effects of ibuprofen 
on migration of HCASMCs. Ibuprofen (500 µM), caused a significant reduction in the 
average mean displacement by HCASMCs over a period of 48 h (Figure 2), further 
confirming the ability of ibuprofen to inhibit migration of HCASMCs cells in vitro. 
 
Ibuprofen induces a phenotypic switch in HCASMCs 
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Previous studies have shown that, during culture in the presence of serum, VSMCs become 
de-differentiated, adopting an amoeboid shape and exhibiting increased synthesis of 
components of the extracellular matrix, thus the term “synthetic” that is commonly used to 
describe this phenotype.[34] Associated with this change in phenotype, de-differentiated 
VSMCs also show a reduced expression of contractile proteins, including SMα-actin, SM22α 
and F-actin.[33, 34] In contrast, serum starvation or treatment with rapamycin, induces 
differentiation of VSMCs with a characteristic spindle shape and increased expression of 
contractile proteins, giving rise to the commonly used term, “contractile” phenotype [33-35] 
Importantly, during vascular damage (e.g. stent deployment), VSMCs migrate and proliferate 
to the site of injury, and this correlates with a change from a contractile towards a synthetic 
phenotype.[15] 
Given the effects of ibuprofen on the proliferation and migration of HCASMCs, we tested the 
possibility that these effects correlate with a change in the de-differentiation state of these 
cells. Therefore, we investigated the morphology of HCASMCs using immunocytochemistry. 
Treatment with 500µM ibuprofen for 72 h induced a change in morphology, from an 
amoeboid into a spindle shape (Figure 3A). Characteristically, the observed change in cell 
surface area induced by ibuprofen mainly affects the width of the treated cell whereas the 
length of the cell remains unchanged (Figure 3B-3D).  
We next investigated whether the changes in morphology induced by ibuprofen correlated 
with changes in expression of markers of the differentiated state.[34] HCASMCs cultured in 
the presence of serum, were either untreated (vehicle controls) or exposed to ibuprofen 500 
µM, and the protein levels of SMα-actin and SM22α were then assessed by immunoblotting 
analysis. As shown in Figure 4A-C, the protein levels of SMα-actin and SM22α were up-
regulated following treatment with ibuprofen for 72 hours. When we analyzed the 
myofilament density of HCASMC, it revealed that treatment with ibuprofen increased the 
phalloidin staining intensity of F-actin, another marker of differentiation of VSMCs,[34] as 
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compared with untreated, vehicle controls (Figure 4D), further supporting the possibility that 
ibuprofen induces a switch from a synthetic to a contractile phenotype in HCASMCs. 
 
The effects of ibuprofen on HCASMCs are partially mediated by PPARγ 
Many effects of NSAIDs are mediated via cyclooxygenase (COX)-independent 
mechanisms;[36] indeed, previous studies have demonstrated that ibuprofen and other 
NSAIDs are agonists of PPARγ.[21-23] On the other hand, the major metabolite of arachidonic 
acid via COX in VSMCs is PGF2α.[37] Interestingly, PGF2α is a selective antagonist of 
PPARγ.[26, 27] To study the molecular mechanisms of the effects of ibuprofen in HCASMCs, 
we evaluated whether the selective natural antagonist of PPARγ, PGF2α,[26, 27] or the 
selective synthetic antagonist, GW9662,[28] could prevent the effects of ibuprofen in 
HCASMCs. 
Figure (5A) shows that the inhibitory effect of ibuprofen on proliferation of HCASMCs was 
almost completely abrogated by pre-incubation with either PGF2α or GW9662. Similarly, 
analysis of migration by wound healing “scratch” assay and time-lapse video-microscopy in 
the presence of either PGF2α or GW9662 in combination with ibuprofen, suggest that the 
PPARγ pathway is also involved in mediating the effects of ibuprofen on HCASMC migration 
(Figures 5B and 5C). Thus, whereas incubation with either antagonist alone does not 
significantly affect the migration of HCASMCs compared to control conditions, incubation of 
HCASMCs with ibuprofen in the presence of either PGF2α or GW9662 significantly, but not 
completely reverses the effects of ibuprofen (Figures 5B and 5C). 
We then explored whether the effects of ibuprofen on morphology and expression of 
markers of differentiation in HCASMCs were also mediated via PPARγ. As shown in Figures 
3A and 3B, cell surface area in HCASMCs treated with ibuprofen in combination with 
GW9662 (3 µM) was similar to that of medium alone-treated control cells, and was 
significantly higher than those treated with ibuprofen alone, suggesting that PPARγ does, 
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indeed, play a role in the phenotype switch induced by ibuprofen. However, whilst GW9662 
significantly inhibits the effects on morphology induced by ibuprofen, they do not return to 
levels seen in untreated, control cells (Figures 3A and 3B), suggesting that other pathways 
might also be involved in mediating these morphological effects. Indeed, troglitazone, a 
selective PPARγ agonist, induces changes in the morphology of HCASMCs but these are 
qualitatively different to those induced by ibuprofen (Figure 3A). Thus, whilst ibuprofen 
induces a change in morphology resembling the characteristic spindle shape of 
differentiated VSMCs as described previously,[34, 35] troglitazone affects both cell width and 
cell length in HCASMCs as opposed to ibuprofen that mainly affects cell width without 
affecting cell length (Figures 3A-3D). Finally, we evaluated the expression of protein markers 
of VSMC differentiation. Significantly, whilst ibuprofen induced expression of both SMα-actin 
and SM22α (Figures 4A-4C, 6A-6C), incubation with PGF2α did not significantly inhibit these 
effects. In fact, SM22α expression levels in the presence of PGF2α alone, or in combination 
with ibuprofen, did not differ; the effect of troglitazone was comparable to that of ibuprofen 
(Figures 6A and 6C). In contrast, whereas PGF2α had a trend to inhibit the effects of 
ibuprofen on SMα-actin expression, this was not significant, and troglitazone failed to induce 
expression of this protein above control levels (Figures 6A and 6B). 
 
Ibuprofen does not affect migration and proliferation of endothelial cells 
Taken together, our results suggest that ibuprofen inhibits proliferation and migration of 
HCASMCs and this is partially mediated by the PPARγ pathway. In clinical practice, the 
ideal DES would prevent restenosis and also late and very late in-stent thrombosis. It has 
been suggested that the currently available DES target VSMC migration and proliferation, 
but in doing so they also prevent re-endothelialisation of the stent struts, with the risk of very 
late in-stent thrombosis steadily occurring over time,[6, 7] indicating that complete healing of 
the vessel wall is never achieved. Novel DES that prevent migration and proliferation of 
VSMCs whilst permitting the migration and proliferation of ECs, and thus allowing re-
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endothelialization, could offer a significant advantage for DES stent therapy. Therefore, we 
performed “scratch” wound assays and time-lapse videomicroscopy analysis to evaluate the 
effects of ibuprofen on migration of HCAECs. 
As shown in Figure 7A, ibuprofen at all concentrations tested (100 – 1000 µM) does not 
significantly affect migration of HCAECs as measured via a “scratch” wound assay. 
Similarly, ibuprofen at a concentration of 750µM, which potently inhibits migration of 
HCASMCs (Figure 1B and Figure 2), fails to inhibit migration of HCAECs as demonstrated 
by time-lapse videomicroscopy analysis (Figure 7B). In contrast, troglitazone does affect 
migration of HCAECs as measured by wound healing assay and time lapse 
videomicroscopy (Figure 7A and Figure 7B). We also evaluated the effects of ibuprofen on 
proliferation of HPMECs. Whilst doses of 100 – 1000 µM had no significant effect on 
proliferation of these cells, there was significant inhibition of proliferation at doses of 2000 
µM, with an estimated IC50 of 1500±50 µM (Figure 7C). Interestingly, this IC50 is up to three 
times higher than that required to inhibit HCASMCs proliferation. Taken together, these 
experiments suggest that the effect of ibuprofen on migration and proliferation at doses 
below 2000 µM is cell type specific thus affecting only HCASMCs while sparing migration 
and proliferation of ECs. 
We next compared the expression levels of PPARγ in both HCASMCs and HCAECs. First, 
we were able to determine that PPARγ, as a nuclear receptor protein, was present mainly in 
the nuclear fractions of both cell types (Figure 8A). To verify the loading of nuclear fractions, 
membranes were probed with ATF2 antibody, and, as shown in Figures 8B and 8C, 
densitometric analysis showed that PPARγ was more abundant in HCASMCs than in 
HCAECs when levels were normalized to the loading control, ATF2 (Figures 8B and 8C). 
Interestingly the protein expressed in both cell types had a molecular mass of ≈53 kDa (see 
Discussion).  
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Discussion 
Restenosis post stent implantation is a complex pathophysiological process, which involves 
proliferation and migration of VSMCs to the site of injury (e.g. following balloon angioplasty 
and stent deployment) and a change in VSMCs towards a synthetic/proliferative 
phenotype.[33] Indeed, the restenotic vessel wall is mostly composed of extracellular matrix 
proteins synthetized by dedifferentiated proliferative VSMCs.[14] Recent advances in stent 
technology, including DES containing antiproliferative agents (e.g. rapamycin and paclitaxel) 
have reduced significantly the rate of restenosis to less than 10% over the past decade.[3, 4] 
However, despite the success of DES in reducing restenosis rates, there is a constant threat 
of late and very late in-stent thrombosis, particularly following abrupt discontinuation of dual 
antiplatelet therapy.[5] Several factors appear to be implicated in the biology of late in-stent 
thrombosis, but most evidence suggests it is the lack of selectivity of DES targeting not only 
VSMCs but also endothelial cells, thus interfering with the process of re-endothelialisation 
and vessel wall repair.[12, 13] Thus, novel compounds capable of selectively targeting VSMCs 
migration and proliferation without interfering with the process of re-endothelialization are 
urgently needed.  Indeed, the ideal stent should be capable of maintaining low rates of 
restenosis, reducing the risk of early or late in stent thrombosis, and promoting vessel wall 
healing by modulating the inflammatory response within the vessel wall.[15, 38] Several second 
generation DES, containing everolimus, or zotarolimus, share the molecular mechanisms of 
their predecessor, sirolimus (rapamycin), and therefore target VSMCs as well as endothelial 
cells. Whilst recent clinical trials suggest improved outcomes compared to first generation 
DES up to 2 years of follow up,[39] their performance in terms of late complications such as 
late and very late (>12 months) stent thrombosis remain to be determined. 
We, and others, have previously shown that certain NSAIDs, including the propionic acid 
derivative, ibuprofen, are capable of reducing rat VSMCs proliferation in a dose- and cell 
cycle-dependent manner.[19, 20] Here, we studied the ability of ibuprofen to inhibit proliferation 
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and migration of HCASMCs. First, we demonstrated that ibuprofen was able to inhibit both 
proliferation and migration of HCASMCs in a dose-dependent manner. Of note, the 
concentration required to inhibit proliferation of HCASMCs (IC50 680±120 µM) is similar to 
the dose that inhibited A10 rat VSMCs proliferation in our previous study (IC50 646 µM).[20] A 
similar concentration range is required for inhibition of HCASMC migration (IC50 410±60 µM) 
as demonstrated by wound healing “scratch” assay and also by time lapse video 
microscopy. Interestingly, we also found that the effects of ibuprofen on HCASMC migration 
and proliferation correlated with the induction of a phenotypic switch on HCASMCs towards 
a differentiated, contractile state, characterized by a spindle shape morphology and 
increased expression of known contractile protein markers of differentiation.[33-35] 
Accumulating evidence indicates that NSAIDs have pleiotropic effects in many cell types, 
and therefore may have a therapeutic role in several conditions including prevention and 
treatment of certain types of cancer,[36] and in prevention and treatment of 
neurodegenerative diseases, such as Alzheimer disease.[22] It has been demonstrated 
previously that Ibuprofen, as well as other NSAIDs, activate PPARγ in several cell types.[21, 
40] Indeed, Ibuprofen at the dose range used in our studies, has been shown to activate the 
PPARγ pathway.[23, 41] In addition, ibuprofen reduces glial inflammation via a PPARγ-
dependent mechanism, thus explaining the beneficial effects of ibuprofen and other NSAIDs 
in Alzheimer’s disease.[23, 42] The report of Weber et al (2000), suggests that the effects of 
ibuprofen on VSMCs proliferation are COX-independent.[19] Significantly, PPARγ appears to 
be protective in the cardiovascular system, and has important regulatory roles in vascular 
biology.[43] Our data indicate that ibuprofen-induced inhibition of HCASMC proliferation 
appears to be mediated primarily by the PPARγ pathway, since pre-incubation with the 
selective PPARγ antagonists, PGF2α and GW9662, almost completely restored the 
proliferative ability of HCASMCs to control levels. To our knowledge, only few studies have 
aimed to elucidate the mechanisms whereby NSAIDs inhibit VSMCs proliferation. One study 
found that several NSAIDs, including ibuprofen, inhibit A10 VSMCs proliferation via inhibition 
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of store operated Ca2+ entry (SOCE) channels, an important Ca2+ entry pathway involved 
in cell proliferation.[44] Another study showed that aspirin inhibited VSMCs proliferation by 
inducing phosphorylation of AMP-activated protein kinase.[45] The precise mechanisms 
whereby ibuprofen via activation of PPARγ inhibit proliferation in VSMCs remain to be 
elucidated; further studies are needed to clarify this. Several agonists of PPARγ have been 
described including thiazolidinediones (e.g. ciglitazone, troglitazone, pioglitazone, 
rosiglitazone), and natural ligands including prostanoids, such as 15d-PGJ2, as well as n3-
polyunsaturated fatty acids.[43] These PPARγ agonists appear to inhibit VSMCs proliferation 
via downstream mechanisms that include, inhibiting the expression of the transcription factor 
c-fos,[46, 47] blockade of Angiotensin-II induced activation of extracellular signal-regulated 
kinase 1/2 (ERK1/2),[18, 48, 49] and suppression of cell cycle signaling through decreased 
phosphorylation of the retinoblastoma protein (Rb),[50] a mediator of G1/S progression, and 
prevention of mitogen induced degradation of p27(Kip1),[50] an inhibitor of  cdk and Rb 
phosphorylation. 
 
The ibuprofen-induced phenotypic switch in HCASMCs also appears to be mediated by 
PPARγ as pre-incubation with GW9662 in the presence of ibuprofen induces a 
dedifferentiated amoeboid morphology similar to that of control cells, whereas incubation 
with ibuprofen alone induces a differentiated spindle-shaped morphology. Similarly, PPARγ 
plays an important role in the migratory activity of HACSMCs as suggested by the partial 
rescue of the migratory activity of these cells by incubation with the PPARγ antagonists, 
PGF2α and GW9662, in the presence of ibuprofen.  
Since the effect of PPARγ inhibitors did not completely abrogate the migratory response, 
other pathways could be involved in this response in addition to PPARγ. We speculate that 
one such pathway could be COX2. Indeed, one of the main metabolites of arachidonic acid 
in VSMCs is PGF2α,[37] and this metabolite is a natural selective antagonist of PPARγ.[26, 27] 
Similarly, in vivo studies have shown that there is increased expression and activity of COX2 
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in the intima following vascular injury.[17, 51] Furthermore, the synthesis of PGF2α via COX 
activity is increased by PDGF,[52, 53] an important regulator of the differentiation state of 
VSMCs, which induces dedifferentiation of VSMCs towards a synthetic phenotype and 
promotes their migration and proliferation.[54-56] In agreement with these observations, our 
preliminary data using the wound healing “scratch” assay, indicate that celecoxib, a COX2 
selective inhibitor, at doses that are non-toxic to the cells (6.25 – 25 µg), prevents migration 
of rat A10 VSMCs whilst sparing HCAECs migration (unpublished observations).  
Of note, our data also indicate that migration and proliferation of ECs is not affected by 
ibuprofen, suggesting that the effect of ibuprofen is cell-type specific. This is an important 
novel finding form our study and to our knowledge this is the first evidence indicating that a 
molecular compound  such as ibuprofen has the ability to selectively inhibit VSMCs 
proliferation and migration while sparing ECs proliferation and migration. The potential 
implications of this observation could translate into the development of novel DES that could 
have advantages over DES currently in use by not only preventing the development of 
restenosis but at the same time, by not interfering with migration and proliferation of ECs, 
facilitate the process of re-endothelialization of the stent struts. The reasons for the 
selectivity of ibuprofen are not clear. PPARγ are ligand-activated transcription factors that 
belong to a nuclear receptor superfamily, of which two isoforms, PPARγ1 (53 kDa) and 
PPARγ2 (57 kDa), are formed from the same gene by alternative mRNA splicing.[57, 58] Our 
results indicate that a single protein band of approximate 53 kDa is detectable in nuclear 
extracts of both HCASMCs and HCAECs (Figure 8), likely corresponding to the PPARγ1 
isoform. This is in agreement with previous studies suggesting that only PPARγ1 is 
expressed in VSMCs and endothelial cells of different species and tissues.[59, 60] We also 
observed that the relative expression levels of PPARγ appear to be higher in HCASMCs 
compared to HCAECs, and this could partly explain the sensitivity of HCASMCs to the 
effects of ibuprofen.  
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Drugs currently used in DES including sirolimus, paclitaxel and zotarolimus inhibit 
proliferation of VSMCs in nano molar concentrations.[61, 62] Thus, a potential limitation of our 
study is that IC50 concentrations of ibuprofen for migration and proliferation appear to be 
very high which may difficult the feasibility of using ibuprofen in a DES. 
Taken together, our results suggest that the in vitro effects of ibuprofen on migration and 
proliferation, coupled with the induction of a phenotype switch towards a differentiated state 
whilst sparing migration of HCAECs, could be exploited by the incorporation of ibuprofen into 
a DES to prevent restenosis post stent implantation and potentially reduce other 
complications of DES stent implantation by not interfering with migration and proliferation of 
ECs. Whether our in vitro observations could be translated clinically into a DES of increased 
performance remains to be demonstrated. Future studies will aim to evaluate the feasibility 
of ibuprofen-containing DES in in vivo animal models of vascular injury and restenosis. 
 
Conclusion 
In conclusion, this study demonstrates for the first time that ibuprofen induces a phenotypic 
change in HCASMCs, which is consistent with the reduced proliferative and migratory ability 
of these cells. The effects of ibuprofen on morphology and proliferation of HCASMCs are 
mediated mainly by the PPARγ pathway. Migration of HCASMCs appears to be mediated in 
part by PPARγ, since pre-incubation with PPARγ antagonists significantly, but not 
completely, reverses the effects of ibuprofen; other pathways (e.g. via COX 2) could be 
involved in this response. Importantly, migration and proliferation of ECs is not affected by 
ibuprofen at concentrations that potently inhibit HCASMCs proliferation and migration, 
indicating that HCASMCs are targeted selectively by ibuprofen. The reasons for the 
selectivity of ibuprofen affecting HCASMCs whereas it spares migration of HCAECs remain 
unclear, but the relatively higher expression levels of PPARγ in HCASMCs could be, at least 
in part, responsible for the sensitivity of HCASMCs to this drug. Our in vitro observations 
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could translate into reduced rates of restenosis post angioplasty with stent deployment of an 
ibuprofen containing DES, providing ibuprofen-induced inhibition of proliferation and 
migration of HCASMCs, and could potentially also lead to a reduced risk of other 
complications following stent implanation, as ibuprofen spares the migration and proliferation 
of ECs. 
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Figure legends 
 
Fig 1. Ibuprofen inhibits migration and proliferation of HCASMCs. A) HCASMCs were either 
untreated (vehicle control) or treated with increasing concentrations of ibuprofen (100 – 1000 
µM). Trypan blue exclusion was used to determine the inhibitory effect of ibuprofen on 
HCASMC proliferation 72 hours after incubation. Ibuprofen causes inhibition of proliferation 
in a dose-dependent manner with an IC
50
 of 680±120 µM. B) HCASMCs were either 
unstimulated (vehicle control), or stimulated with increasing concentrations of ibuprofen for 
24h. Mitomycn C was added at 23 h (1 hour before “scratch” wound) to prevent unwanted 
proliferation. Wound healing “scratch” assay was then performed as described in Materials 
and Methods. Ibuprofen causes inhibition of migration in a dose-dependent manner with an 
IC
50
 of 410±160 µM (100 – 1000 µM). Data shown in A and B are representative of 3-4 
independent experiments. C) Representative images of the effects of ibuprofen (500 µM and 
750 µM) versus control on migration of HCASMCs. *p<0.05, by one way ANOVA with 
Dunnett’s multiple comparison test. 
 
 
Fig 2. Ibuprofen inhibits migration of HCASMCs. Time lapse video microscopy of the effects 
of ibuprofen (500 µM) compared to control. Data are presented as bar and whisker graphs 
and are representative of three independent experiments and are shown as mean ±SEM of 
average migrated displacement (AMD). *p < 0.05 as compared to controls. 
 
 
Fig 3. Ibuprofen induces a phenotypic switch in HCASMCs. A)-C) HCASMCs were 
untreated (control) or exposed to troglitazone (100 µM) or GW9662 (3 µM) alone or in 
combination with ibuprofen (500 µM) for 72 hours. A) Cells were immunostained; pictures 
are representative of three independent experiments. Scale bar = 50 µm. B) Areas; C) 
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lengths; and, D) widths, were measured for at least 40 cells in each experiment. Results are 
means ± SEM for three independent experiments. *p < 0.05,** p < 0.01 one way ANOVA 
with Tukey’s post test. 
 
 
Fig 4. Ibuprofen increases the expression of protein markers of differentiation. A) HCASMCs 
were unstimulated (control) or exposed to 500 µM ibuprofen for 72 h and expression of SM 
α-actin and SM22α protein levels were assessed by immunoblotting. Images are 
representative of three independent experiments. B) and C), densitometric analyses of 
immunoblotts. Data presented as mean ± SEM for three independent experiments. D) 
fluorescence intensity analysis of F-actin expression on HCASMCs untreated (control) or 
exposed to 500 µM for 72 hours. F-actin fibers were stained with Alexa Fluor® 594 
phalloidin. *p < 0.05 paired two-tailed student t test. 
 
 
Fig 5. The effects of ibuprofen on proliferation and migration of HCASMCs is mediated via 
PPARγ. A) HCASMCs were either untreated (vehicle controls) or exposed to either PGF2α 
(100 nM) or GW9662 (3 µM) in the presence or absence of ibuprofen (500µM). Trypan blue 
exclusion was used to evaluate HCASMC proliferation. B) Cells were untreated (vehicle 
controls) or exposed to either PGF2a or GW9662 in the presence or absence of ibuprofen 
(500µM) for 72 h. Mitomycn C (0.5 µg/ml) was added at 1 hour before the “scratch” wound to 
prevent unwanted proliferation. Wound healing “scratch” assay was then performed. C) Time 
lapse video microscopy of the effects of ibuprofen (500 µM) on migration of HCASMCs in the 
presence or absence of GW9662 compared to vehicle controls and troglitazone (100 µM). 
Data are presented as bar and whisker graphs and are representative of three independent 
experiments and are shown as mean ± SEM of average migrated displacement (AMD). *p < 
0.05 one way ANOVA with Tukey’s post test. 
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Fig 6. Ibuprofen-mediated expression of protein markers of differentiation is not dependent 
on PPARγ. A) immunoblotting analysis of markers of contractile proteins expressed in 
HCASMCs in response to troglitazone (100 µM), or ibuprofen 500 µM alone or in 
combination with PGF2α (100 nM) versus vehicle control. B) and C), densitometric analyses 
of immunoblots relative to GAPDH. Data presented are mean ± SEM from three 
independent experiments. *p < 0.05 one way ANOVA with Tukey’s post test. 
 
 
Fig 7. Ibuprofen does not affect migration and proliferation of endothelial cells. A) HCAECs 
were untreated, exposed to different concentrations of ibuprofen (100 µM – 1000 µM), or 
exposed to troglitazone (100 µM) for 24 h. Results shown are mean ± SEM for three 
independent experiments. *p < 0.05 one way ANOVA with Tukey’s post test. B) Time lapse 
video microscopy on HCAECs treated with troglitazone (100 µM) or GW9662 (3 µM) alone 
or in combination with ibuprofen (500 µM). Data are presented as bar and whisker graphs 
and are representative of three independent experiments and are shown as mean ± SEM of 
average migrated displacement (AMD). C) Human pulmonary microvascular endothelial 
cells (HPMECs) were either untreated (vehicle control) or treated with increasing 
concentrations of ibuprofen (100 – 2000 µM). Direct cell counting using Trypan blue 
exclusion was used to determine the inhibitory effect of ibuprofen on HPMECs proliferation 
72 hours after incubation. Ibuprofen causes inhibition of proliferation in a dose-dependent 
manner with an IC50 of 1500±50 µM. *p<0.05, by one way ANOVA with Dunnett’s multiple 
comparison test. 
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Fig 8. PPARγ is mainly a nuclear protein and is more abundantly expressed in HCASMCs 
relative to HCAECs. A) and B) immunoblotting analysis of PPARγ expression in untreated 
HCASMCs vs HCAECs. A) PPARγ is mainly expressed in the nucleus. B) Representative 
images of immunoblotting for PPARγ in HCASMCs versus HCAECs. C) densitometric 
analysis showing relative abundance of PPARγ normalised to ATF2 protein as loading 
control. 
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